Canaccord lowered the firm’s price target on HealthStream (HSTM) to $21 from $25 and keeps a Hold rating on the shares. The firm said HealthStream’s 4Q’25 results were respectable amid rising concerns of AI disintermediation of SaaS names. Management addressed the AI concerns on the conference call, making a compelling case how HealthStream is more favorably positioned than other software names in the broader landscape.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HSTM:
- HealthStream: Solid Q4 Beat, Durable Subscription-Driven Growth, and Platform Strategy Underpin Buy Rating
- HealthStream Reports Record Q4 Revenue and Raises Dividend
- HealthStream sees FY26 revenue $323M-$330M, consensus $315.29M
- HealthStream reports Q4 adjusted EPS 18c, two estimates 17c
- Is HSTM a Buy, Before Earnings?